FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...
A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought. A new study led by researchers at the UCLA Health ...
It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results